The medicinal cannabis purveyor Bioxyne was the top performing ASX biotech in 2024-25, recording a 300% share gain. ... Read ...

Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

This is the first-in-human phase 1/2a trial of Treg and bone marrow transplantation in HLA-mismatched living donor kidney transplant recipients.

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...

TikTok is a particularly valuable platform for helping find matches because it targets younger audiences, said Erica Jensen, ...

So, we marked another World Sickle Cell Day on Thursday, June 19. But truthfully, what was there to celebrate? I can’t speak ...

A panelist discusses how the historical standard of care for metastatic squamous cell anal carcinoma evolved from ...

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options. A new ...

Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hemat ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...